Effective High-dose Interferon-α Therapy in a 13-Year-Old Girl With Erdheim-Chester Disease

Area of Science:

• Histiocytosis and Proliferative Disorders
• Pediatric Hematology/Oncology
• Rare Genetic Diseases

Background:

• Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis typically affecting adults, characterized by multisystemic involvement.
• While bone is commonly affected, ECD can impact the central nervous system, cardiovascular system, and other organs.
• Pediatric cases of ECD are exceptionally rare, presenting unique diagnostic and therapeutic challenges.

Observation:

• A 13-year-old girl with multisystemic involvement was diagnosed with Erdheim-Chester disease.
• The B-Raf proto-oncogene V600E mutation, often associated with histiocytic disorders, was notably absent in the patient's ECD lesions.
• The patient received high-dose interferon-alpha therapy for her condition.

Findings:

• The pediatric patient with Erdheim-Chester disease exhibited an excellent response to high-dose interferon-alpha treatment.
• The absence of the B-Raf V600E mutation in this case suggests alternative pathogenic mechanisms in pediatric ECD.
• Review of pediatric ECD case reports highlights the variability in presentation and treatment outcomes.

Implications:

• This case underscores the potential efficacy of interferon-alpha in treating pediatric Erdheim-Chester disease, even in the absence of common mutations.
• Understanding the molecular drivers in pediatric ECD is crucial for developing targeted therapies.
• Further research into rare histiocytic disorders in children is warranted to improve diagnostic accuracy and treatment strategies.